AbCellera Biologics (ABCL) Retained Earnings (2020 - 2026)

AbCellera Biologics has reported Retained Earnings for 7 years, with the latest figure at -$2.4 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 103.39% year-over-year to -$2.4 million; the trailing twelve-month figure through Mar 2026 stood at -$2.4 million (down 103.39% YoY), and the FY2025 full-year result was -$29.5 million, down 573.41% from the prior year.
• Retained Earnings for Q1 2026 stood at -$2.4 million, up from -$29.5 million in the prior quarter.
• The five-year high for Retained Earnings was $456.1 million in Q3 2022, with the low at -$29.5 million in Q4 2025.
• Historically, Retained Earnings has averaged $194.9 million across 5 years, with a median of $202.2 million in 2024.
• Annual changes were most pronounced in 2022 — Retained Earnings jumped 19856.04% — and 2025, when it sank 573.41%.
• AbCellera Biologics' Retained Earnings stood at $426.2 million in 2022, then sank by 34.35% to $279.8 million in 2023, then sank by 101.56% to -$4.4 million in 2024, then slumped by 573.41% to -$29.5 million in 2025, then soared by 91.79% to -$2.4 million in 2026.
• The last three Retained Earnings figures came in at -$2.4 million (Q1 2026), -$29.5 million (Q4 2025), and -$20.5 million (Q3 2025), per Business Quant data.